Clinical trial · Interventional
Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients
Preemptive Therapy Study of Cetuximab(Erbitux®)Induced Skin Rash Using Doxycycline, Sunscreen, Hydrocortisone and Moisturizer in Colorectal and Head and Neck Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine if using preventive treatments such as Doxycycline (an anti-biotic) capsules, sunscreen with SPF 30, Hydrocortisone 1% cream and a moisturizer will help to reduce the incidence and severity of the skin rash associated with Cetuximab (Erbitux®) when compared to receiving standard care for the treatment of skin rash.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clindamycin | Drug | — | UNRESOLVED |
| Doxycycline | Drug | — | UNRESOLVED |
| Hydrocortisone 1% cream | Drug | — | UNRESOLVED |
| Medrol-dose pack (Steroid) | Drug | — | UNRESOLVED |
| Moisturizer | Other | — | UNRESOLVED |
| Sunscreen | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Extensive treatment group
- description
- Doxycycline capsule, 100 mg, taken twice daily; sunscreen SPF 30 or higher applied to exposed skin areas at least 30 minutes before going outdoors each morning; moisturizer applied to the face, hands, feet, neck, back, and chest each morning after sunscreen; Hydrocortisone 1% topical cream applied to the face, hands, feet, neck, back, and chest each evening. For patients with grade 1 rash, hydrocortisone 1% cream and clindamycin 1% gel (tetracycline antibiotic) are recommended for daily use. For patients with grade 2 rash, hydrocortisone cream and doxycycline 100mg twice daily or minocycline (tetracycline antibiotic) 100mg once daily is recommended. For patients with grade 3 rash, systemic steroid therapy (a Medrol dose-pack) will be added to the grade 2 treatment.
- interventionNames
- Drug: Doxycycline
- Drug: Hydrocortisone 1% cream
- Other: Sunscreen
- Other: Moisturizer
- Drug: Clindamycin
- Drug: Medrol-dose pack (Steroid)
- type
- EXPERIMENTAL
- label
- Standard care group
- description
- Patient will not receive preventive treatment but will be allowed to use sunscreen and moisturizer if desired.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age greater than or equal to 18 years 2. Diagnosis of colorectal or head and neck cancer 3. Receipt of at least one dose of cetuximab during the study time period Exclusion Criteria: 1. Prior cetuximab treatment within the 6 months of study initiation 2. Current treatment with tyrosine kinase inhibitors 3. Patients who are pregnant or incarcerated
References
Publications (0)
Data not yet available